Scientists aren’t sure exactly what causes renal cell carcinoma. They know that most kidney cancers start when something goes wrong in the genes in the kidney. No one can say for certain why ...

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

Compared with other ablative therapies, stereotactic body radiotherapy might offer a ‘particularly advantageous option’ for ...

Renal cell carcinoma is the most common form of kidney cancer. It can take time to fully process a diagnosis and what, ...

In the early stages, the cancer mass (tumor) is small and doesn’t always cause symptoms. About 25% of people with renal cell carcinoma do not experience any symptoms at all. If you do develop ...

A study identified a link between sex hormones and renal cell carcinoma, suggesting potential new treatment strategies.

Some cancer cells have what are called checkpoint proteins known as PD-L1 on their cell surface ... Keytruda can cause very serious side effects. These include problems in your lungs, intestines ...

The following is a summary of “Metabolic syndrome and increased susceptibility to renal cell carcinoma – a meta-analysis,” ...

Renal cell carcinoma (RCC) refers to a heterogenous group of cancers that originate in the proximal convoluted tubule of the kidney. The three most common forms of RCC are clear cell RCC ...

Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in Renal Cell Carcinoma) study underscore the critical role of tumor size ...

Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.

According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially serious toxicities that should be closely monitored.